Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 4Terminated 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

Cyclophosphamide 12fludarabine 11fludarabine phosphate 8Tacrolimus 8Melphalan 8Whole-Body Irradiation 7Mycophenolic Acid 7Thiotepa 6Imatinib Mesylate 6nilotinib 5Granulocyte Colony-Stimulating Factor 5Dasatinib 5Busulfan 5venetoclax 4ponatinib 4asciminib 4Mesna 4bosutinib 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3thymoglobulin 2ruxolitinib 2blinatumomab 2Patient Reported Outcome Measures 2Filgrastim 2Antilymphocyte Serum 2selinexor 1plerixafor 1Triamcinolone 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × ruxolitinib × Clear all
NCT05088356 2026-05-12

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1 Active not recruiting
66 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03610971 2026-04-02

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡